Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs
Completed · Not applicable · NCT02985684
Conditions: Atrial Septal Defect
At a glance
- Research payments reported, 2025
- $3,500
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 125
About the trial
- Sponsor
- W.L.Gore & Associates
- Tested
- GORE® CARDIOFORM ASD Occluder (device)
- Dates
- Started 2017-03-10; completion 2022-09-29
- Results posted
- Yes
Evaluate the safety and efficacy of the GORE® CARDIOFORM ASD Occluder in the percutaneous closure of ostium secundum atrial septal defects (ASDs)
From ClinicalTrials.gov, last updated 2026-03-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
W. L. Gore & Associates, Inc. reported $3,500 in research payments for this study in 2025 (3 payments).
Products named: Product in Development
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jeremy D. Asnes, MD Pediatric Cardiology · New Haven, CT
- Donald J. Hagler SR., M.D. Pediatric Cardiology · Rochester, MN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mayo Clinic $3,250
- Yale University $250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.